Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner (Q47388835)

15 January 2018

title

Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner (English)

1 reference

15 January 2018

author name string

Yochai Birnbaum

1

1 reference

15 January 2018

Bo Long

2

1 reference

15 January 2018

Jinqiao Qian

3

1 reference

15 January 2018

Jose R Perez-Polo

4

1 reference

15 January 2018

Yumei Ye

5

1 reference

15 January 2018

publication date

1 March 2011

1 reference

15 January 2018

Basic Research in Cardiology

published in

1 reference

15 January 2018

volume

106

1 reference

15 January 2018

issue

3

1 reference

15 January 2018

page(s)

431-446

1 reference

15 January 2018

https://scigraph.springernature.com/pub.10.1007/s00395-011-0162-3

exact match

0 references

cites work

Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Kinases and phosphatases in ischaemic preconditioning: a re-evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Survival kinases in ischemic preconditioning and postconditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Controlling cardiomyocyte length: the role of renin and PPAR-γ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth fac

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive ox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

15-Deoxy-delta12,14-prostaglandin-J(2) up-regulates cyclooxygenase-2 but inhibits prostaglandin-E(2) production through a thiol antioxidant-sensitive mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Ischemic postconditioning in pigs: no causal role for RISK activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00395-011-0162-3

10.1007/S00395-011-0162-3

21 January 2018

Identifiers

DOI

1 reference

15 January 2018

PubMed ID

21360043

1 reference

15 January 2018